High-Efficiency Cell-Type Proteomics Strategy Deciphers Cholangiocarcinoma Fibrosis-Associated Pathological Heterogeneity

Analytical Chemistry, Journal Year: 2025, Volume and Issue: unknown

Published: March 3, 2025

Cholangiocarcinoma (CCA) is the second most common primary liver cancer and characterized by huge heterogeneity, difficult diagnosis, poor prognosis. Fibrosis-associated heterogeneity in CCA serves as an indicator of malignant progression cancer; however, a precise approach to deciphering fibrosis still lacking. Typically, tissue proteome profiled analyzing bulk tissues, which gives average results different cell types, especially for tissues cells occupy very small proportion. Laser microdissection (LMD) can precisely dissect clusters, but required manual, time-consuming annotation limits its efficiency. Herein, we develop π-CellSeg-CCA, pathological image analysis algorithm based on Mask R-CNN ResNet-18, enable automated normal bile duct regions LMD achieve enhanced recognition accuracy ∼90%. Driven new strategy integrating machine learning algorithm, LMD, simple integrated spintip-based proteomics technology (SISPROT), high-sensitivity mass spectrometry decipher fibrosis-associated heterogeneity. We identify over 8000 proteins, including marker proteins specifically expressed from only 1 mm2 samples. A protein upregulated CCA, MUC16, further investigated reveal association with worse prognosis contribution CCA. expect that algorithm-assisted cell-type promising studying tumor microenvironment limited clinical materials.

Language: Английский

Radiomics predicting immunohistochemical markers in primary hepatic carcinoma: current status and challenges

Heliyon, Journal Year: 2024, Volume and Issue: 10(23), P. e40588 - e40588

Published: Nov. 20, 2024

Primary hepatic carcinoma, comprising hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), and combined (cHCC-CCA), ranks among the most common malignancies worldwide. The heterogeneity of tumors is a primary factor impeding efficacy treatments for carcinoma. Immunohistochemical markers may play potential role in characterizing this heterogeneity, providing significant guidance prognostic analysis development personalized treatment plans patients with Currently, immunohistochemical primarily relies on invasive techniques such as surgical pathology tissue biopsy. Consequently, non-invasive preoperative acquisition immunohistochemistry has emerged focal point research. As an emerging diagnostic technique, radiomics possesses to extensively characterize tumor heterogeneity. It can predict associated preoperatively, demonstrating auxiliary utility clinical guidance. This article summarizes progress using addresses challenges faced field study, anticipates its future application prospects.

Language: Английский